Global Personalized Medical Devices Market Outlook, 2031

The global personalized medical devices industry covers devices designed, manufactured, configured or adapted for the individual patient, including patient-specific implants and surgical guides produced with 3D printing from medical images, custom prosthetics and orthotics, hearing aids fitted to individual hearing profiles, clear aligners and dental restorations designed for each patient's teeth, automated insulin delivery systems and continuous glucose monitors that adapt therapy to individual data, programmable neurostimulators, personalised wearable sensors and software-driven devices that use artificial intelligence to tailor treatment. Personalisation ranges from fully custom-made devices to mass-produced devices whose settings or algorithms adapt to each user. Leading companies include Stryker, Zimmer Biomet, Johnson & Johnson MedTech, Enovis, which acquired LimaCorporate in 2024, Materialise, restor3d, 3D Systems, Align Technology, Straumann, Dentsply Sirona, Sonova, Demant, WS Audiology, GN, Cochlear, Apple, Medtronic, Dexcom, Abbott, Insulet, Tandem Diabetes Care, Ottobock and Össur. Enabling technologies include medical imaging, computer-aided design, additive manufacturing, biocompatible materials, cloud software, sensors and AI, and regulators have developed specific pathways for patient-matched and adaptive devices.

Personalisation has become a central theme in medical technology, driven by digital design, 3D printing and data. Patient-specific knee, hip, shoulder, spine and craniofacial implants and surgical guides are increasingly used for complex cases, and hospitals are setting up point-of-care 3D printing laboratories. Consumer technology has also blurred boundaries: the US FDA created a category of over-the-counter hearing aids in October 2022, allowing adults with mild to moderate hearing loss to buy them without a prescription, and in September 2024 the FDA authorised a hearing aid feature for Apple's AirPods Pro 2, which uses a personalised hearing test to tune sound. In diabetes, automated insulin delivery systems adjust insulin based on each person's glucose readings, and over-the-counter continuous glucose monitors such as Dexcom's Stelo, cleared in March 2024, and Abbott's Lingo brought personalised glucose data to people without insulin-treated diabetes. Regulators have adapted to software that learns and changes, with the FDA issuing final guidance in December 2024 on predetermined change control plans for AI-enabled devices, allowing approved devices to update algorithms within agreed limits. Industry restructuring continues, including Medtronic's plan announced in 2025 to separate its diabetes business. Challenges include manufacturing costs for custom devices, reimbursement, data privacy and cybersecurity, and demonstrating better outcomes than standard devices.

Market Dynamics Market Drivers • Advances in Imaging, Design Software and 3D PrintingHigh-resolution CT and MRI, computer-aided design and additive manufacturing allow devices to be designed around each patient's anatomy and produced quickly in metals, polymers and ceramics. Patient-specific implants and guides can improve fit, reduce surgery time and help in complex cases where standard implants fail. Falling costs of 3D printing and software make personalised devices more accessible to hospitals and manufacturers.
• Data-Driven and Adaptive TherapiesSensors, connectivity and AI enable devices that continuously adapt to each patient, including automated insulin delivery, closed-loop neurostimulation, personalised hearing aid tuning and smart inhalers. Consumers increasingly expect personalised health technology, and wearable devices provide continuous data that can guide individual treatment. Regulators' frameworks for updating AI algorithms support ongoing personalisation.

Market Challenges • Cost, Reimbursement and EvidenceCustom devices often cost more to design and produce than standard devices, and payers may not reimburse the extra cost without evidence of better outcomes. Clinical studies of personalised devices are difficult because each device differs. Hospitals must invest in imaging, planning software and staff time, and reimbursement codes for patient-specific devices and digital personalisation are limited in many countries.
• Regulatory Complexity, Data Privacy and CybersecurityRegulating devices that are unique to each patient or that change their behaviour through software requires new approaches to validation and quality control. Point-of-care manufacturing in hospitals raises questions about responsibility. Personalised devices collect sensitive health data, creating privacy and cybersecurity risks, and connected devices must meet growing security requirements from regulators.

Market Trends • Point-of-Care Manufacturing and Patient-Specific ImplantsHospitals are establishing in-house 3D printing laboratories to produce anatomical models, surgical guides and, in some cases, implants, often in partnership with companies such as Materialise, Stratasys and 3D Systems. Orthopaedic companies are expanding patient-specific implant ranges, and restor3d and others offer personalised implants for foot, ankle, shoulder and spine. Regulators are clarifying requirements for point-of-care manufacturing.
• Consumer-Grade Personalised Health DevicesConsumer electronics companies and medical device makers are converging, with over-the-counter hearing aids, hearing features on earbuds, over-the-counter continuous glucose monitors, smartwatches with ECG and blood pressure features and personalised sleep and fitness devices. These products bring personalised monitoring to large populations and generate data that clinicians can use, while raising questions about accuracy and regulation.



Segment Analysis Orthopaedic and dental devices account for the largest share of custom-manufactured personalised devices, while diabetes, hearing and neurology devices lead in software-driven personalisation. Orthopaedic devices include patient-specific joint replacement implants, cutting guides, spinal implants, craniomaxillofacial plates and custom implants for complex revisions and bone tumours, produced by Stryker, Zimmer Biomet, Johnson & Johnson MedTech, Enovis, restor3d and others. Dental devices, including clear aligners from Align Technology and competitors, crowns, bridges, implants and surgical guides designed digitally and produced by milling or 3D printing, represent one of the largest personalised device categories. Hearing devices, including hearing aids fitted to individual hearing loss, over-the-counter hearing aids and cochlear implants programmed for each user, form a large segment. Diabetes devices, including automated insulin delivery systems, insulin pumps and continuous glucose monitors, personalise therapy through algorithms. Prosthetics and orthotics, including custom sockets, microprocessor-controlled knees and 3D-printed orthoses from Ottobock, Össur and others, are designed for each user. Neurological devices, including deep brain stimulators and spinal cord stimulators programmed or adapted to individual signals, form another segment. Cardiovascular devices, including patient-specific stent grafts for complex aortic aneurysms and personalised pacing, and ophthalmic devices such as custom intraocular lenses, add further categories.

3D printing and additive manufacturing is the leading technology for custom physical devices, while AI and closed-loop software is the fastest-growing technology for adaptive personalisation. 3D printing and additive manufacturing, using metal powder bed fusion, stereolithography and other methods, produces patient-specific implants, surgical guides, dental devices, prosthetic sockets and hearing aid shells directly from digital designs, and it has become central to personalised device production. Computer-aided design and virtual surgical planning software, from companies such as Materialise, converts medical images into device designs and surgical plans. CNC milling remains important for dental crowns and some implants. AI and machine learning personalise device behaviour, including hearing aid sound processing, insulin dosing algorithms, image-based implant planning and neurostimulation settings. Closed-loop systems combine sensors and actuators, such as continuous glucose monitors linked to insulin pumps and neurostimulators that sense brain or spinal signals. Wearable sensors collect continuous physiological data used to tailor care. Bioprinting, which prints living cells and biomaterials, is an early-stage technology for personalised tissues. Digital twins, virtual models of individual patients used to simulate device performance, are being explored in cardiology and orthopaedics.

Hospitals and surgical centres are the main end users of patient-specific implants and surgical devices, while home and consumer settings account for the fastest growth through wearable and adaptive devices. Hospitals and ambulatory surgical centres use patient-specific implants, surgical guides and anatomical models for orthopaedic, craniofacial, cardiovascular and oncological surgery, and some operate point-of-care 3D printing laboratories. Dental clinics and laboratories are major users of personalised dental devices, often working with digital scanners and design software. Audiology clinics and hearing care retailers fit hearing aids and cochlear implants. Specialty clinics, including diabetes, neurology and orthopaedic clinics, prescribe and program personalised devices. Home care and consumer settings have become important as patients use automated insulin delivery systems, continuous glucose monitors, over-the-counter hearing aids and wearable devices at home, often connected to smartphone apps and cloud platforms. Prosthetic and orthotic clinics design and fit custom devices. Rehabilitation centres use personalised exoskeletons and assistive devices. Research institutions develop new personalisation technologies. Retail pharmacies and consumer electronics stores sell over-the-counter personalised devices.

Implantable personalised devices account for a large share of value, while non-invasive and wearable personalised devices account for the largest number of users. Implantable personalised devices include patient-specific orthopaedic and craniofacial implants, dental implants, cochlear implants, neurostimulators, pacemakers with personalised settings and custom stent grafts, and they generate high value per device. Non-invasive and external devices include hearing aids, clear aligners, prosthetics, orthotics and personalised surgical guides used during procedures. Wearable devices, including continuous glucose monitors, insulin pumps, smartwatches and wearable sensors, reach the largest number of users and are growing rapidly with over-the-counter availability. Software as a medical device, including apps and algorithms that personalise treatment recommendations, forms a growing category that can be paired with hardware or used alone. Surgical planning products, including anatomical models and virtual planning services, support personalised surgery. Assistive devices, including personalised wheelchairs, exoskeletons and communication devices, serve people with disabilities. The distinction between medical and consumer devices is blurring as consumer products gain medical features and regulatory clearance.

Regional Analysis North America leads the personalized medical devices market because of high adoption of patient-specific implants, digital dentistry, diabetes technology and consumer health devices, while Europe is a major innovation centre and Asia-Pacific is the fastest-growing region. North America, led by the United States, accounts for the largest share of the personalized medical devices market. The United States has high use of patient-specific orthopaedic implants, clear aligners, automated insulin delivery and continuous glucose monitoring, and a large number of point-of-care 3D printing programmes in hospitals. The FDA created an over-the-counter hearing aid category in 2022, authorised the AirPods Pro 2 hearing aid feature in 2024, cleared over-the-counter glucose monitors in 2024 and issued final guidance on predetermined change control plans for AI devices in December 2024, supporting personalised and adaptive devices. Major companies, including Stryker, Zimmer Biomet, Align, Dexcom, Insulet, Tandem and Apple, are based in the United States. Canada has similar adoption patterns. Europe is a major region and innovation centre, with companies such as Materialise in Belgium, Sonova in Switzerland, Demant and GN in Denmark, Straumann in Switzerland, Ottobock in Germany, Össur in Iceland and LimaCorporate in Italy, now part of Enovis, and strong academic work on 3D printing and personalised prosthetics under the EU Medical Device Regulation, which also covers custom-made devices. Asia-Pacific is the fastest-growing region, with rising adoption of digital dentistry, hearing aids and diabetes technology in China, Japan, South Korea, India and Australia, and growing 3D printing manufacturing capacity in China. Latin America, the Middle East and Africa have smaller markets with growing adoption in private healthcare.

Key Developments 2025: Medtronic announced plans to separate its diabetes business, which makes insulin pumps and automated insulin delivery systems, into a standalone company.
December 2024: The FDA issued final guidance allowing AI-enabled devices to include plans for future algorithm updates within agreed limits, supporting adaptive and personalised device software.
September 2024: The FDA authorised the first over-the-counter hearing aid software for use with consumer earbuds, using a personalised hearing test to adjust sound.
March 2024: Dexcom's Stelo became the first continuous glucose monitor cleared for over-the-counter use by adults not using insulin, expanding personalised glucose monitoring.
January 2024: Enovis completed its acquisition of LimaCorporate, a maker of orthopaedic implants with patient-specific and 3D-printed implant capabilities.
October 2022: A new FDA rule allowed adults with perceived mild to moderate hearing loss to buy hearing aids without a medical exam or prescription.

Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global Personalized Medical Devices Market with its value and forecast along with its segments
• Various drivers and challenges
• Ongoing trends and developments
• Top profiled companies
• Strategic recommendation

By Device Type
• Orthopaedic Devices
• Dental Devices
• Hearing Devices
• Diabetes Devices
• Prosthetics and Orthotics
• Neurological Devices
• Cardiovascular Devices

By Technology
• 3D Printing and Additive Manufacturing
• Computer-Aided Design and Surgical Planning
• AI and Closed-Loop Software
• Wearable Sensors

By End User
• Hospitals and Surgical Centres
• Dental Clinics and Laboratories
• Specialty Clinics
• Home Care and Consumer Settings

By Invasiveness
• Implantable Devices
• Non-Invasive and External Devices
• Wearable Devices
• Software as a Medical Device